Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Biogen Inc.

Start price
Target price
Perf. (%)
€265.69
29.12.18
€297.66
04.11.21
-8.92%
05.11.21

buy
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€44.54
27.12.18
€53.22
04.11.21
14.78%
05.11.21

buy
Illumina Inc.

Start price
Target price
Perf. (%)
€272.37
07.01.19
€343.44
04.11.21
36.18%
05.11.21

buy
Resmed Inc.

Start price
Target price
Perf. (%)
€92.39
11.10.18
€187.32
04.11.21
143.85%
05.11.21

buy
Align Technology

Start price
Target price
Perf. (%)
€289.85
11.10.18
€455.96
04.11.21
103.07%
05.11.21

buy
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€47.22
19.04.18
€62.00
04.11.21
8.26%
05.11.21

buy
Abbott Laboratories

Start price
Target price
Perf. (%)
€86.80
20.04.20
€120.00
04.11.21
28.11%
04.11.21

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.89
09.01.21
€68.00
09.01.22
8.15%
30.10.21

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
buy
Merck & Co. Inc.

Start price
Target price
Perf. (%)
€71.50
01.03.19
€77.00
04.11.21
-1.04%
26.10.21

Could be worthwhile Investment >10% per year
buy
Becton, Dickinson & Co.

Start price
Target price
Perf. (%)
€222.00
01.02.21
€260.00
30.03.22
-6.17%
09.10.21

Pfizer Inc.

Start price
Target price
Perf. (%)
€39.50
28.08.21
-
28.08.22
0.10%
04.09.21

Risky Investment
buy
Humana Inc.

Start price
Target price
Perf. (%)
€370.00
01.05.21
-
01.05.22
-5.65%
02.09.21

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Higher risks for its business
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.50
30.11.20
€38.00
30.11.21
18.40%
02.08.21

Could be worthwhile Investment >10% per year
Very high dividend yield expected
Fair valuation
Higher EBIT margin than peer group
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.79
27.01.21
-
27.01.22
6.17%
28.07.21

buy
Perrigo Co. plc

Start price
Target price
Perf. (%)
€37.00
15.02.21
-
15.02.22
5.95%
11.07.21

Could be worthwhile Investment >10% per year
Undervalued
Higher risks for its business
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€33.31
09.07.21
-
09.07.22
0.27%
09.07.21

Top 10 in its market
Small cyclical dependencies
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€56.02
06.04.21
€60.00
06.04.22
3.82%
01.07.21

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€152.98
25.03.21
€140.00
25.09.21
25.83%
28.06.21

Could be worthwhile Investment >10% per year
Known brand
Medium risks for its business
overvalued
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€178.02
29.10.19
€190.00
04.11.21
-11.04%
17.06.21

Could be worthwhile Investment >10% per year
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€275.40
22.04.20
€320.00
04.11.21
17.79%
17.06.21

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€69.00
29.03.20
€80.00
04.11.21
-15.28%
17.06.21

Could be worthwhile Investment >10% per year
Undervalued
High dividend yield expected
positive Cash Flow expected
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€56.50
20.10.20
€60.00
04.11.21
-11.63%
07.06.21

Could be worthwhile Investment >10% per year
Abiomed Inc.

Start price
Target price
Perf. (%)
€266.60
29.04.21
€245.00
29.04.22
-10.43%
07.06.21

Could be worthwhile Investment >10% per year
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.93
05.01.21
-
05.01.22
10.78%
03.06.21

Could be worthwhile Investment >10% per year
Capable Management
Innovative
Market Leader or Top 3
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
06.02.21
-
06.02.22
7.91%
25.05.21

EBIT growth >5% per year expected
Very low/no dividend yield expected